Loading...
SUN Pharmaceutical Industries Limited — Tobramycin Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #2 for Tobramycin · $3.9M export value · DGFT Verified
SUN Pharmaceutical Industries Limited is the #2 Indian exporter of Tobramycin with $3.9M in export value and 77 verified shipments. SUN Pharmaceutical Industries Limited holds a 9.8% market share in Tobramycin exports across 4 countries. The company exports 118 pharmaceutical products worth $979.8M across 25 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| BELGIUM | $2.4M | 62 | 63.2% |
| UNITED STATES | $1.0M | 23 | 28.1% |
| AUSTRALIA | $300.0K | 6 | 8.1% |
| RUSSIA | $25.5K | 2 | 0.7% |
SUN Pharmaceutical Industries Limited exports Tobramycin to 4 countries. The largest destination is BELGIUM accounting for 63.2% of SUN Pharmaceutical Industries Limited's Tobramycin shipments, followed by UNITED STATES (28.1%) and AUSTRALIA (8.1%). These destinations reflect SUN Pharmaceutical Industries Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| YUSEN LOGISTICS BENELUX BELGIUM | BELGIUM | $1.8M | 47 |
| YUSEN LOGISTICS BENELUX BELGIUM KEETBERGLAAN | BELGIUM | $595.8K | 15 |
| SUN PHARMACEUTICAL INDUSTRIES,INC. | UNITED STATES | $534.8K | 11 |
| SUN PHARMA ANZ PTY LTD | AUSTRALIA | $300.0K | 6 |
| SUN PHARMACEUTICAL INDUSTRIES INC |
India exported $20.8M worth of Tobramycin through 2,676 shipments from 283 suppliers to 134 countries, serving 580 buyers globally. SUN Pharmaceutical Industries Limited contributes $3.9M to this total, accounting for 9.8% of India's Tobramycin exports. SUN Pharmaceutical Industries Limited ships Tobramycin to 4 countries through 10 buyers.
SUN Pharmaceutical Industries Limited's average Tobramycin shipment value is $50.0K per consignment, based on 77 shipments totaling $3.9M. The largest destination is BELGIUM (63.2% of SUN Pharmaceutical Industries Limited's Tobramycin exports).
SUN Pharmaceutical Industries Limited ranks #2 among 283 Indian Tobramycin exporters with a 9.8% market share. The top 3 exporters are MANKIND PHARMA LIMITED ($3.9M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($3.9M), SENTISS PHARMA PRIVATE LIMITED ($3.0M). SUN Pharmaceutical Industries Limited processed 77 shipments to 4 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| TOBRAMYCIN SUN 300MG/5MLNEBULIZER SOLUTI | $641.4K | 18 |
| TOBRAMYCIN SUN 300MG/5ML NEBULIZER SOLUT | $289.3K | 8 |
| TOBRAMYCIN SUN 300MG/5ML NEBULIZER SOLUTION TOBRAMYCIN 300MG/5ML NEBULISER SOLUTION [351 PACK X 4 X 14 = 19656 NOS] | $269.7K | 6 |
| Tobramycin Inhalation Solution USP, 300 | $200.0K | 4 |
| TOBRAMYCIN INHALATION SOLUTION USP 300 | $200.0K | 4 |
| TOBRAMYCIN SUN 300MG/5ML NEBULIZER SOLUTION TOBRAMYCIN 300MG/5ML NEBULISER SOLUTION [475 PACK X 4 X 14 = 26600 NOS] | $150.0K | 3 |
| TOBRAMYCIN SUN 300MG/5ML SOLUTION FOR INHALATION (TOBRAMYCIN 300MG/5ML NEBULISERSOLUTION) [1000 PACK X 4X14 =56000 NOS]NOS | $150.0K | 3 |
| TOBRAMYCIN INHALATION SOLUTION USP, 300MG/5 ML PACK : 04*14 BATCH : BAE0386A/BAE0378A MFD : 30.11.2023/28.11.2023 EXP :NOS |
What SUN Pharmaceutical Industries Limited must comply with to export Tobramycin to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Approval Process
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | MANKIND PHARMA LIMITED | $3.9M | 78 | 2 | $50.0K |
| 2 | SUN PHARMACEUTICAL INDUSTRIES LIMITED ★ | $3.9M | 77 | 4 | $50.0K |
| 3 | SENTISS PHARMA PRIVATE LIMITED | $3.0M | 60 | 1 | $50.0K |
| 5 | MYLAN LABORATORIES LIMITED | $2.3M | 45 | 2 |
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 454 | 17.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 329 | 12.3% |
| DELHI AIR | 316 | 11.8% |
| SAHAR AIR | 298 | 11.1% |
| NHAVA SHEVA SEA (INNSA1) | 93 | 3.5% |
| CHENNAI AIR CARGO ACC (INMAA4) | 88 | 3.3% |
| Delhi Air | 86 | 3.2% |
| Bombay Air | 79 | 3.0% |
Sun Pharma's export operations, valued at $979.8 million, are significantly influenced by current geopolitical events. The ongoing Israel-Iran tensions have led to disruptions in the Red Sea shipping routes, a critical corridor for Indian pharmaceutical exports to Europe and North Africa. Major shipping lines have imposed 'Emergency Risk Surcharges,' increasing freight costs and extending transit times by 10–15 days. These delays pose risks to the integrity of time-sensitive and temperature-controlled pharmaceutical shipments. (pharmaceuticalcommerce.com)
In the United States, policy shifts towards domestic manufacturing and the imposition of tariffs on imported pharmaceuticals have created challenges for Indian exporters. Sun Pharma, which supplies a substantial portion of generics to the U.S. market, faces potential reductions in export volumes due to these protectionist measures. The company is exploring strategies such as establishing local partnerships and investing in U.S.-based manufacturing to mitigate these impacts. (odrindia.in)
The European Union's implementation of the Carbon Border Adjustment Mechanism (CBAM) introduces additional compliance requirements for exporters. Sun Pharma must adapt to these regulations to maintain its market presence in the EU, necessitating investments in sustainable manufacturing practices and comprehensive reporting mechanisms. (sgeexport.com)
Compliance with international regulatory standards remains a critical focus for Sun Pharma. The company has encountered challenges with the U.S. FDA, including import alerts and non-compliance letters for certain facilities. Addressing these issues involves implementing corrective actions and awaiting reinspection to resume full operations. (business-standard.com)
Globally, the pharmaceutical industry faces increasing scrutiny regarding quality standards. Sun Pharma's commitment to adhering to Good Manufacturing Practices (GMP) and other regulatory requirements is essential to maintain its export licenses and market reputation. Continuous investment in quality control systems and compliance infrastructure is imperative to navigate the evolving regulatory landscape.
SUN Pharmaceutical Industries Limited exports 118 products worth $979.8M. Beyond Tobramycin, top products include Strip, Esomeprazole, Magnesium, Calcium, Omeprazole. View the complete SUN Pharmaceutical Industries Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Tobramycin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for SUN Pharmaceutical Industries Limited's Tobramycin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
SUN Pharmaceutical Industries Limited
Full Company Profile →
118 products · $979.8M total trade · 25 categories
| UNITED STATES |
| $250.0K |
| 5 |
| SUN PHARMACEUTICAL INDUSTRIES, INC. | UNITED STATES | $169.6K | 4 |
| SUN PHARMACEUTICAL INDUSTRIES,INC, | UNITED STATES | $50.0K | 1 |
| SUN PHARMACEUTICAL INDUSTRIESINC. | UNITED STATES | $41.6K | 2 |
| AO "RANBAXY" | RUSSIA | $17.4K | 1 |
| AO RANBAXY - | RUSSIA | $8.1K | 1 |
SUN Pharmaceutical Industries Limited supplies Tobramycin to 10 buyers globally. The largest buyer is YUSEN LOGISTICS BENELUX BELGIUM (BELGIUM), followed by YUSEN LOGISTICS BENELUX BELGIUM KEETBERGLAAN (BELGIUM) and SUN PHARMACEUTICAL INDUSTRIES,INC. (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| $149.4K |
| 3 |
| TOBRAMYCIN INHALATION SOLUTION USP,300 M | $100.0K | 2 |
| TOBRAMYCIN SUN 300MG/5MLNEBULIZER SOLUTION (FOR FRANCE) / TOBRAMYCIN 300 MG/5 MLNEBULISER SOLUTION BP (For EU) PACK: 04 | $100.0K | 2 |
SUN Pharmaceutical Industries Limited exports 41 distinct Tobramycin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is TOBRAMYCIN SUN 300MG/5MLNEBULIZER SOLUTI with 18 shipments worth $641.4K.
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| $50.0K |
SUN Pharmaceutical Industries Limited ranks #2 among 283 Indian Tobramycin exporters. Average shipment value of $50.0K compared to the market average of $73.4K. The closest competitors by value are MANKIND PHARMA LIMITED and SENTISS PHARMA PRIVATE LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 134+ countries, 580+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for SUN Pharmaceutical Industries Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Tobramycin. For current shipment-level data, contact TransData Nexus.